



Nombres:

FRANCISCO JAVIER

Apellidos:

RIVERA GOMEZ-BARRIS

Contacto (Opcional):

FRANCISCO.RIVERA@PMU.AC.AT

Título Profesional o Grado Académico (incluya el año de obtención):

LICENCIADO EN BIOTECNOLOGIA MOLECULAR (2000)

INGENIERO EN BIOTECNOLOGÍA MOLECULAR (2002)

Estudios de Postgrado o Especialización (institución donde lo obtuvo y año de obtención):

DOCTOR EN CIENCIAS CON MENCIÓN EN BIOLOGIA MOLECULAR, CELULAR Y NEUROCIENCIAS (FACULTAD DE CIENCIAS-UNIVERSIDAD DE CHILE, 2006)

Actividad Actual e Institución en la cual trabaja:

INVESTIGADOR POSTDOCTORAL (INSTITUTO DE MEDICINA MOLECULAR REGENERATIVA, UNIVERSIDAD MEDICA PARACELSUS, SALZBURG, AUSTRIA)

Reseña de su actividad laboral actual:

Multiple sclerosis (MS) is a demyelinating immune-mediated disease of the central nervous system (CNS). It is the most common cause of acquired disability in young adults and affects over 2 Mio people worldwide. Current treatments target primarily the immune system, reduce the relapse rate and the formation of inflammatory lesions in the CNS, however with only temporary and limited success. The identification of neural and oligodendroglial progenitors in the adult CNS evoked the hypothesis that remyelination might be achieved in respond to demyeliation during MS. Indeed, spontaneous remyelination is a common feature in MS, but its levels and its qualities are apparently insufficient for a sustained endogenous functional repair. We have recently shown that bone marrow derived mesenchymal stem cells (MSCs) induced oligodendrocyte fate decision and differentiation on adult neural progenitor cells. Our current efforts aim to decipher the MSCs derived oligodendrogenic molecular mechanism and to develop future molecular and cellular therapies to enhance remyelination in MS and after spinal cord injury.